Date: 2018-07-23
Type of information: Production agreement
Compound: siplizumab
Company: BioInvent (Sweden) ITBMed (Sweden)
Therapeutic area: Transplantation - Technology - Services
Type agreement: manufacturing - bioproduction
Action mechanism:
- monoclonal antibody. Siplizumab is a monoclonal antibody directed towards the human CD2 molecule, a 50 kDa transmembrane glycoprotein, that has a central role particularly in T lymphocyte function. In humans, CD2 is expressed on all mature T lymphocytes, 95% of thymocytes and the majority of NK cells. It functions as either an adhesion or a co-stimulation molecule. The interaction between the CD2 and its ligand CD58 (LFA-3) mediates adhesion between T cells and antigen-presenting cells, thereby enhancing antigen recognition via the CD3-antigen-MHC receptor. The CD2 molecule is also the target for an activating signal and T cell activation that can be induced in the absence of accessory cells by co-stimulation with anti-CD2 and anti-CD3 mAb .
- Unless T cell activation is controlled, transplant rejection will be initiated. Thus, there is a clear immunologic rationale why a blocking anti-CD2 mAb can function as an immunomodulatory agent in vivo in organ transplantation. The CD2 molecule has multiple binding sites, and siplizumab uniquely targets a specific part of the CD2 antigen, inhibits T cell proliferation and is able to induce alloantigen-specific hyporesponsiveness.
Disease:
Details:
- • On July 23, 2018, BioInvent International announced that the company has signed a production agreement with the Swedish biopharmaceutical company ITBMed. Under the agreement, BioInvent will perform cGMP manufacturing of the anti-CD2 monoclonal antibody, siplizumab, for ITBMed’s ongoing clinical trials.
Financial terms:
- The production agreement is expected to generate revenue of at least SEK 17 million in 2018 and 2019.
Latest news:
Is general: Yes
